文献速递银屑病与炎症性皮肤病

基于iTRAQ的定量蛋白质组学揭示可预测甲氨蝶呤治疗银屑病疗效的生物标志物/通路

iTRAQ-based quantitative proteomics reveals biomarkers/pathways in psoriasis that can predict the efficacy of methotrexate.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-06-24

研究采用iTRAQ技术检测4例甲氨蝶呤应答良好者、4例不应答者和4例正常对照的外周血单个核细胞蛋白表达,并在18例银屑病患者中分析。共鉴定403个差异表达蛋白,其中ANXA6、GPV、FN1、XRCC6、STOM、RPS27A和EZR等7个蛋白可能作为预测甲氨蝶呤疗效的生物标志物。

要点

  • iTRAQ检测鉴定出403个差异表达蛋白(倍数变化≥1.2,P<0.05)。
  • 应答良好者中ANXA6、RPS27A、EZR、XRCC6上调,GPV、FN1、STOM下调。
  • ANXA6和STAT1在应答良好者中显著下调,在不应答者中无此变化。

核心结论

  • 鉴定出7个差异表达和调控的蛋白(ANXA6、GPV、FN1、XRCC6、STOM、RPS27A和EZR)作为预测甲氨蝶呤治疗银屑病疗效的生物标志物,涉及NF-κB信号通路、JAK-STAT通路、中性粒细胞脱颗粒、血小板活化、信号传导和聚集。

研究设计与样本

  • 采用iTRAQ技术定量检测4例甲氨蝶呤应答良好者、4例不应答者和4例正常对照的外周血单个核细胞蛋白表达,并在18例银屑病患者中分析鉴定与甲氨蝶呤疗效相关的蛋白。

主要发现

  • 共3177个蛋白具有定量信息,鉴定出403个差异表达蛋白(倍数变化≥1.2,P<0.05)。
  • 与正常对照相比,应答良好者中参与NF-κB活化、JAK-STAT通路和中性粒细胞脱颗粒的上调蛋白(ANXA6、RPS27A、EZR、XRCC6)被检测到。
  • 应答良好者中涉及血小板活化、信号传导和聚集以及中性粒细胞脱颗粒的蛋白(GPV、FN1、STOM)显著下调,这些蛋白在甲氨蝶呤治疗后恢复至正常水平。
  • Western blotting鉴定外周血单个核细胞中ANXA6和STAT1的表达在应答良好者中显著下调,但在不应答者中未显著下调。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Methotrexate (MTX) is the first-line medicine to treat psoriasis. So far, there has been less research on protein biomarkers to predict its efficacy by the proteomic technique. OBJECTIVES: To evaluate differentially expressed proteins in peripheral mononuclear cells (PBMCs) between good responders (GRs) and non-responders (NRs) after MTX treatment, compared with normal controls (NCs). METHODS: We quantified protein expression of PBMCs with four GRs and four NRs to MTX and four NCs by isobaric tags for relative and absolute quantification (iTRAQ), analysing and identifying proteins related to efficacy of MTX in 18 psoriatic patients. RESULTS: A total of 3177 proteins had quantitative information, and 403 differentially expressed proteins (fold change ≥1.2, P < 0.05) were identified. Compared to NCs, upregulated proteins (ANXA6, RPS27A, EZR, XRCC6), participating in the activation of NF-κB, the JAK-STAT pathway and neutrophil degranulation were detected in GRs. The proteins (GPV, FN1, STOM), involving platelet activation, signalling and aggregation as well as neutrophil degranulation were significantly downregulated in GRs. These proteins returned to normal levels after MTX treatment. Furthermore, Western blotting identified the expression of ANXA6 and STAT1 in PBMCs, which were significantly downregulated in GRs, but not in NRs. CONCLUSIONS: We identified seven differentially expressed and regulated proteins (ANXA6, GPV, FN1, XRCC6, STOM, RPS27A and EZR) as biomarkers to predict MTX efficacy in NF-κB signalling, JAK-STAT pathways, neutrophil degranulation, platelet activation, signalling and aggregation.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Yan KX, Meng Q, He H, et al. iTRAQ-based quantitative proteomics reveals biomarkers/pathways in psoriasis that can predict the efficacy of methotrexate. J Eur Acad Dermatol Venereol. 2022. PMID: 35666151. doi:10.1111/jdv.18292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。